Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors.

ABSTRACT: Utilization of tumor-only sequencing has expanded in pediatric cancer patients, which can lead to identification of pathogenic variants in genes that may be germline and/or have uncertain relevance to the tumor in question, such as the homologous recombination (HR) pathway genes BRCA1/2. We identified patients with pathogenic BRCA1/2 mutations from somatic tumor sequencing, and performed additional germline sequencing to assess for the presence of loss of heterozygosity (LOH). Of seven patients identified, four (57.1%) mutations were found in the germline and none had associated LOH. Our data suggest that BRCA1/2 mutations identified in this context are likely incidental findings.

SUBMITTER: Groves A 

PROVIDER: S-EPMC10883645 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature